Vaccine Market Tops 37 Billion, Says Kalorama Information Report
In 2020, the global market for preventive vaccines is valued at $37.4 billion, up overall from $30.7 billion in 2015. The finding was made in Kalorama Information’s report, Vaccines 2020. Strong continued growth in the global vaccines market is expected through 2025.
THE MOST CURRENT VACCINE MARKET INFORMATION
The vaccine market is a growth market for the experienced competitors participating in it.Seven billion dollars in new sales have occurred in the past five years alone, and vaccines have been developed and deployed for new diseases. COVID-19 has only intensified the focus on the the potential of vaccines, the market was already expanding prior to the pandemic, and many vaccines for new conditions are under developments. Kalorama has covered the vaccines market for two decades. During that time our analysts have detailed the growth of the market.
“Seven billion dollars in new sales have occurred in the past five years alone. Growth will be fueled by favorable demographics, continued new product introductions, indication expansions, usage and more.”
This report examines the market for these vaccines used to prevent various types of disease, and provides market modeling by disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines for diseases that are not currently vaccine-preventable, such as addiction and malaria. The report also discusses trends and looks at what vaccine companies have done and are planning. It also covers the COVID-19 vaccine market landscape, development progress and estimated market opportunity as of October 2020.
A HIGH-GROWTH, CONSTANTLY DEVELOPING MARKET
Vaccines Market, $BN, 2015, 2020 and 2025
Because of the large number of deadly diseases that have been virtually eliminated through the proliferation of effective vaccines, vaccination is generally viewed as one of the greatest public health achievements during the 20th century. As a result of widespread public vaccination, vaccine-preventable diseases and their resulting deaths are now rare in the developed nations and declining worldwide. Immunizations have eradicated smallpox; eliminated poliomyelitis in the Americas; and controlled measles, rubella, tetanus, diphtheria.
FACTORS DRIVING GROWTH
Cost-effectiveness: Vaccines reduce healthcare costs associated with vaccine-preventable diseases. It is estimated that every dollar invested in vaccination returns between $7 and $20 in averted healthcare costs;
Aging population: As senior citizens are more susceptible to certain vaccine-preventable diseases such as influenza, more vaccine products are required to meet the needs of this growing global population;
Mobility: As people become increasingly mobile, diseases historically confined to remote areas of the world are becoming global problems;
Advancing technology: New technologies will fuel the development of vaccines that are safer, more effective and more cost effective to produce than existing vaccines;
Usage of vaccines in more countries: WHO and other initiatives to expand immunization programs continue to increase the usage of vaccines in countries with previously poor vaccination records;
Rising public awareness: Direct-to-consumer (DTC) advertising and other public awareness programs will continue to expand consumer awareness of the importance of vaccination;
Government recommendations: Governments around the world continue to review and expand vaccination recommendations;
Indication expansions: Manufacturers are increasingly expanding the populations for which their vaccines may be utilized;
Healthcare Reform: Because all ACIP-recommended vaccines are covered under Healthcare Reform, millions of Americans who were previously uninsured now have coverage for vaccines;
Healthcare decentralization: Expansion of retail health clinics and urgent care centers makes vaccination available to persons without strong health coverage;
Greater expansion is mitigated, however, by continued negative public perceptions of vaccine safety, shortages, funding challenges
KALORAMA INFORMATION’S REPORT PROVIDES
CRITICAL INSIGHTS FOR BUSINESS PLANNING
As part of its offering this report involves the following data points and others:
Influenza Vaccine Global Market, 2020-2025
US, European, and ROW Vaccine Markets by Type (Hepatitis, Combinations, Meningitis, Pneumococcal, Rotavirus, Influenza, HPV, Shingles, Others)
Major Manufacturers’ Shares of the Global Vaccine Market, 2020
Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, HPV, Others) 2020–2025
Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020–2025
Selected Pediatric Vaccines in Development, 2020
Selected Adult Vaccines in Development, 2020
COVID-19 Vaccine Developments
COVID-19 Vaccine Potential Market Estimate, High Case and Low Case
Development of new vaccines is ongoing. Generally speaking, vaccine clinical development in the world’s major markets follows a similar pathway as drugs and other biologics. A sponsor who wishes to begin clinical trials with a vaccine must first obtain permission to conduct clinical studies. In the U.S., this requires the submission of an Investigational New Drug (IND) application to the FDA.
“mitigating against growth will be continuing concerns about vaccine safety and refusal to immunize.”
The IND describes the vaccine, its method of manufacture, and quality control tests for release. Also included is information about the vaccine’s safety and ability to elicit a protective immune response (immunogenicity) in animal testing as well as the proposed clinical protocol for studies in humans. Kalorama’s report tracks development of vaccines, including those for COVID-19.
The report as well reviews the history and lines of business, strategic alliances, vaccine products, and financial information of market leaders such as GlaxoSmithKline, Merck, Pfizer, and Sanofi Pasteur.
COMPANY COVERAGE
Companies Covered in the Report Include:
ADVAXIS BAVARIAN NORDIC, A/S BHARAT BIOTECH INTERNATIONAL CSL LIMITED/SEQIRUS EMERGENT BIOSOLUTIONS GLAXOSMITHKLINE HAWAII BIOTECH IMMUNE RESPONSE BIOPHARMA INOVIO PHARMACEUTICALS JOHNSON & JOHNSON/CRUCELL/JANSSEN MEDICAGO MERCK & CO MITSUBISHI TANABE PHARMA CORPORATION MODERNA NOVAVAX PFIZER SANOFI PASTEUR SERUM INSTITUTE SOLIGENIX TAKEDA PHARMACEUTICAL CO VALNEVA SE
MARKET SIZING – MARKET FORECASTS – COMPANY SEGMENTATION – COMPANY SHARE – COMPANY PROFILES Reserve Your Copy of This Report Today
Adult Vaccines in Development
More Detailed Information with Report Purchase
Company
Product Name
Indication
Status
Altimmune
NasoVAX
Influenza
Phase IIb
Merck
V503 – SILGARD 9
HPV
Approved (Japan)
Merck
V920 – ERVEBO
Ebola
Approved (US/EU)
Emergent BioSolutions
CHIKV VLP
Chikungunya
Phase II
Emergent BioSolutions
FLU-IGIV
Influenza A
Phase II
GlaxoSmithKline
GSK3437949A
Malaria
Phase II
HeloCyte
Triplex
CMV
Phase II
Valneva
VLA84
C. difficile
Phase II completed
Soligenix
RiVax
B ricin
Phase IIb
Takeda
TAK-214
Norovirus
Phase IIb
ISR
ISR-48
HIV
Phase IIb-III
Bavarian Nordic
MVA BN
Smallpox
Phase III
Crucell/Janssen
VAC89220
HIV
Phase III
Novavax
NanoFlu
Influenza
Phase III
Pfizer
PF 06425090
C. difficile
Phase III
Sanofi Pasteur
NIRSEVIMAB
RSV
Phase III
Takeda
TAK-003
Dengue
Phase III
Valneva
VLA 84
C. difficile
Phase III
Medicago/Mitsubishi Tanabe
Quadrivalent VLP Influenza
Influenza
Phase III (Europe)
Janssen
VAC52150
Ebola
Phase III (US)
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
THE GLOBAL VACCINES INDUSTRY
SCOPE AND METHODOLOGY
MARKET ESTIMATES AND FORECASTS
Figure 1-1: Global Vaccine Market, 2020 – 2025, $M
CHAPTER 2: INTRODUCTION TO VACCINES
INTRODUCTION
Table 2-1: Global Morbidity of Vaccine Preventable Diseases in 1990 vs. 2019
Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
A BRIEF HISTORY: THE DEVELOPMENT OF VACCINES
THE HUMAN IMMUNE SYSTEM
VACCINE MECHANISM OF ACTION
TYPES OF VACCINES
Attenuated (Weakened) Live Viruses
Figure 2-2: Attenuated Virus Production
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
VACCINE APPROVAL PROCESS
Table 2-2: VAERS Table of Reportable Events Following Vaccination
WORLD HEALTH ORGANIZATION PREQUALIFIED VACCINES
Table 2-3: WHO Prequalified BCG Vaccines
Table 2-4: WHO Prequalified Cholera Vaccines
Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
Table 2-11: WHO Prequalified Hepatitis A Vaccines
Table 2-12: WHO Prequalified Hepatitis B Vaccines
Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
Table 2-14: WHO Prequalified Influenza Vaccines
Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
Table 2-16: WHO Prequalified Measles Vaccines
Table 2-17: WHO Prequalified Measles and Rubella Vaccines
Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
Table 2-19: WHO Prequalified Meningococcal A Vaccines
Table 2-20: WHO Prequalified Pneumococcal Vaccines
Table 2-21: WHO Prequalified Polio Vaccines
Table 2-22: WHO Prequalified Rabies Vaccines
Table 2-23: WHO Prequalified Rotavirus Vaccines
Table 2-24: WHO Prequalified Rubella Vaccines
Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
Table 2-26: WHO Prequalified Typhoid Vaccines
Table 2-27: WHO Prequalified Varicella Vaccine
Table 2-28: WHO Prequalified Yellow Fever Vaccines
PANDEMICS
HIN1 Pandemic of 2009/2010
Coronavirus Pandemic
Figure 2-3: COVID-19 Per Capita Doses Ordered by Country
Figure 2-4: COVID-19 Vaccine Candidates: Government Presales
Ebola Epidemic 2014-2016
Manufacturing Incentives
Synthetic Vaccines
ARTIFICIAL INTELLIGENCE DEVELOPMENT
CHAPTER 3: PEDIATRIC PREVENTATIVE VACCINES
INTRODUCTION
Table 3-1: Global Child Immunization Rates for Vaccines Recommended by the WHO, 2019
CHILDHOOD IMMUNIZATION IN THE UNITED STATES
Childhood Immunization Rates
Challenges to the Vaccine Delivery System
Recommended Childhood Immunization Schedule
Figure 3-1: CDC Recommended Immunization Schedule: Birth to 15 Months
Figure 3-2: CDC Recommended Immunization Schedule: 18 Months to 18 Years
State Immunization Recommendations
Figure 3-3: Polar Graph on State School Vaccination Exemptions Law, United States
United Nations Initiatives
PEDIATRIC VACCINE MARKETS
Table 3-2: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020–2025, in $ Millions
Figure 3-4: Global Market for Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020–2025 (%)
Figure 3-5: Market Share of Pediatric Preventive Vaccines by Type (Hepatitis, Pediatric Routine (HiB, MMR, Combinations, Polio, Varicella), Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Others) 2020 (%)
PEDIATRIC VACCINES IN DEVELOPMENT
Table 3-3: Selected Pediatric Vaccines in Development, 2020
COMPETITIVE SUMMARY
Table 3-4: Major Manufacturers’ Shares of the Global Pediatric Preventative Vaccine Market, 2020 (%, $ Millions)
Figure 3-6: 2020 Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (%)
CHAPTER 4: ADULT PREVENTATIVE VACCINES
INTRODUCTION
RECOMMENDED ADULT IMMUNIZATIONS
Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
GLOBAL INFLUENZA SURVEILLANCE PROGRAM
U.S. Surveillance
Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004 – 2020 (%)
WHO International Health Regulations
Influenza
Figure 4-2: U.S. Flu Season Severity from 2008 to 2018
Table 4-2: WHO Pandemic Classification Schedule
ADULT PREVENTIVE VACCINE MARKETS
Table 4-3: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020–2025, in $ Millions
Figure 4-3: Global Market for Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020–2025 (%)
Figure 4-4: Market Share of Adult Preventive Vaccines by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Travel & Other) 2020 (%)
Influenza Vaccine Market: Generating 28% of Total Adult Vaccine Sales
Figure 4-5: U.S. Seasonal Influenza Vaccination by Age Group and Season, 2010-2020
Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target – Total Population – Seasons 2010-2020
COVID-19 Market Size Estimates and Forecast
ADULT VACCINES IN DEVELOPMENT
Table 4-4: Selected Adult Preventive Vaccines in Development, 2020
COVID-19 Vaccine Development
Figure 4-7: Regional Distribution of COVID-19 Vaccine Development
Figure 4-8: COVID-19 Vaccine Development, Distribution by Vaccine Platform
Table 4-5: Select Vaccines in Development for COVID-19 – Phase I through Phase III
COMPETITIVE SUMMARY
Table 4-6: Major Manufacturers’ Shares of the Global Adult Preventative Vaccine Market, 2020 (%, $ Millions)
Figure 4-9: 2020 Global Adult Preventative Vaccines Market Share, by Leading Competitors (%)
CHAPTER 5: TOTAL VACCINES MARKET
TRENDS DRIVING THE VACCINES MARKET
Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
MARKET SIZE AND FORECAST
Table 5-1: Total Global Market for Preventive Vaccines by Type, 2020–2025, in $ Millions
Figure 5-2: Total World Market for Vaccines by Type, 2015-2024 (Pediatric, Adult) ($ Millions) 1
Adult Vaccines
Figure 5-3: Global Preventive Vaccine Market by Broad Segment (Pediatric, Adult), Trend 2015 – 2025 $millions
Vaccine Sales by Region
Table 5-2: Total U.S. Market for Preventive Vaccines by Type, 2020–2025, in $ Millions
Table 5-3: Total Europe Market for Preventive Vaccines by Type, 2020–2025, in $ Millions
Table 5-4: Total ROW Market for Preventive Vaccines by Type, 2020–2025, in $ Millions
VACCINE MARKET COMPETITORS
Table 5-5: Major Manufacturers’ Shares of the Global Vaccine Market, 2020 (%, $ Millions)
Figure 5-4: 2020 Global Vaccines Market Share, by Leading Competitors (%)
COVID-19 VACCINE MARKET
Table 5-6: Global COVID-19 Vaccine Market Forecast, 2021 ($ millions)
